Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
The use of a high-grade sunblock is suggested
Worked example: GHK-Cu 50 mg vial Large vials like the 50 mg GHK-Cu require special attention
Elevating and compressing the legs and monitoring can also prevent swelling
THE CUSTOMER ACKNOWLEDGES THAT THERE ARE RISKS IN THE HANDLING, USE, AND DISTRIBUTION OF THESE PRODUCTS, AND CERTIFIES THAT IT HAS THE PROPER EQUIPMENT, FACILITIES, AND PERSONNEL FOR MANAGING THOSE RISKS
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
